Virally-induced tumorigenesis controlled by the microbiota

由微生物群控制的病毒诱导的肿瘤发生

基本信息

  • 批准号:
    10667586
  • 负责人:
  • 金额:
    $ 46.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract Retroviruses induce a broad range of tumors in vertebrates. Although some retroviruses carry oncogenes in their genome, the vast majority of retroviruses do not encode such elements and thus, their capacity to induce tumors depends on integration near cellular proto-oncogenes. However, oncogene activation alone is not sufficient for tumor induction and additional events are required for tumor development. Murine Leukemia Virus (MuLV), which can spread as an oral and as a blood-borne pathogen, is highly proficient in causing leukemia. Intriguingly, tumor incidence within the same strain of infected mice varies between different facilities. Among environmental factors that may differ between the research labs, the variation in gut microbiota stands out.Thus, we sought to determine whether the microbiota contributes to virally-induced leukemogenesis. Accordingly, we monitored virally-induced leukemia in germ-free (GF, sterile) and specific pathogen free (SPF) conventionally raised BALB/cJ mice. Even though MuLV replication and spread were not affected in the absence of the microbiota, GF mice were significantly more resistant to the leukemia than SPF mice. Colonizing GF mice with a defined group of commensal bacteria (Altered Schaedler’s Flora), or with a single bacterium such as Lactobacillus murinus but not Parabacteroides distasonis or similar to E. coli and shigella (SECS) did not change virus replication but abolished the tumor-resistant phenotype of the colonized mice, indicating that some gut microbes have tumor-promoting properties. At the same time, GF mice lacking adaptive immune system (T and B lymphocytes) developed leukemia at a high rate suggesting that the gut microbes facilitate leukemia promotion by counteracting the adaptive immune response. Gene- expression analysis of the pre-leukemic spleens revealed several negative regulators induced by the microbiota. Among those, the ‘V-set and Ig domain-containing 4’ (VSig4) gene, a known negative regulator of T-cell responses attracted our interest because it was found upregulated in various human cancers. The gut microbiota has been implicated in both progression of cancers of colon and liver (‘local’ influence), as well as in systemic anti-cancer effect by enhancing the effect of anti-cancer immunotherapy. There is also a hint that the microbial environment can influence development of non-virally induced lymphomas. To identify the mechanism(s) by which the gut microbiota promotes leukemia, we will use our expertise in virology, mammalian genetics and gnotobiotic technologies (Dr. Golovkina, University of Chicago) and expertise in bacterial genetics and metabolomics (Dr. Fischbach, Stanford University). The goals of the proposal are: to determine the role of microbially regulated-VSig4 in virally-induced leukemogenesis; to characterize the bacterial compound(s) responsible for virally-induced leukemia development; to determine whether the gut microbiota influences leukemia development in a non-viral model of cancer.
摘要 逆转录病毒在脊椎动物中诱导广泛的肿瘤。虽然有些逆转录病毒携带 尽管逆转录病毒在其基因组中含有致癌基因,但绝大多数逆转录病毒不编码这些元件,因此,它们的 诱导肿瘤的能力取决于细胞原癌基因附近的整合。然而,癌基因 单独的活化不足以诱导肿瘤,肿瘤发展需要额外的事件。 小鼠白血病病毒(MuLV),可以作为口腔和血液传播的病原体传播, 擅长引发白血病有趣的是,同一品系的感染小鼠的肿瘤发病率不同 在不同的设施之间。在研究实验室之间可能存在差异的环境因素中, 因此,我们试图确定微生物群是否有助于 病毒诱导的白血病因此,我们在无菌(GF,无菌) 和无特定病原体(SPF)的常规饲养的BALB/cJ小鼠。尽管MuLV复制和 在没有微生物群的情况下,GF小鼠的传播没有受到影响,GF小鼠对微生物群的抵抗力明显更强。 SPF小鼠的白血病。用确定的一组肠道细菌(Altered Schaedler's)定殖GF小鼠 植物群),或与单一细菌如鼠乳杆菌(Lactobacillus murinus),但不与Parabacteroides distasonis或类似物 与大肠大肠杆菌和志贺氏菌(SECS)没有改变病毒复制,但消除了肿瘤的耐药表型, 这表明某些肠道微生物具有促肿瘤特性。与此同时,GF 缺乏适应性免疫系统(T和B淋巴细胞)的小鼠发生白血病的几率很高,这表明 肠道微生物通过抵消适应性免疫反应来促进白血病的发生。吉恩 白血病前脾的表达分析揭示了由细胞因子诱导的几种负调节因子。 微生物群在这些基因中,已知的V-set和含有IG结构域的4(VSig 4)基因是V-set的负调节因子。 T细胞反应引起了我们的兴趣,因为它被发现在各种人类癌症中上调。 肠道微生物群与结肠癌和肝癌(“局部”)的进展有关。 影响),以及通过增强抗癌免疫疗法的效果而在全身抗癌效果中。 还有一个暗示,微生物环境可以影响非病毒诱导的发育, 淋巴瘤为了确定肠道微生物群促进白血病的机制,我们将使用我们的 病毒学、哺乳动物遗传学和微生物技术方面的专门知识(芝加哥大学Golovkina博士) 以及细菌遗传学和代谢组学方面的专业知识(Fischbach博士,斯坦福大学)。的目标 建议是:确定微生物调节的VSig 4在病毒诱导的白血病发生中的作用; 表征导致病毒诱导白血病发展的细菌化合物;以确定 肠道微生物群是否影响非病毒癌症模型中白血病的发展。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Gut commensal bacteria enhance pathogenesis of a tumorigenic murine retrovirus.
  • DOI:
    10.1016/j.celrep.2022.111341
  • 发表时间:
    2022-09-13
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Spring, Jessica;Khan, Aly A.;Lara, Sophie;O'Grady, Kelly;Wilks, Jessica;Gurbuxani, Sandeep;Erickson, Steven;Fischbach, Michael;Jacobson, Amy;Chervonsky, Alexander;Golovkina, Tatyana
  • 通讯作者:
    Golovkina, Tatyana
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL ANDREW FISCHBACH其他文献

MICHAEL ANDREW FISCHBACH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL ANDREW FISCHBACH', 18)}}的其他基金

Building the foundations of commensal vaccines
建立共生疫苗的基础
  • 批准号:
    10478380
  • 财政年份:
    2022
  • 资助金额:
    $ 46.74万
  • 项目类别:
Building the foundations of commensal vaccines
建立共生疫苗的基础
  • 批准号:
    10709507
  • 财政年份:
    2022
  • 资助金额:
    $ 46.74万
  • 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
  • 批准号:
    10189532
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
  • 批准号:
    10206257
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
  • 批准号:
    10447071
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
  • 批准号:
    9751590
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
Virally-induced tumorigenesis controlled by the microbiota
由微生物群控制的病毒诱导的肿瘤发生
  • 批准号:
    10425354
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic disease
项目 3:微生物群在心脏代谢疾病中产生芳基硫酸盐和次级胆汁酸
  • 批准号:
    10653055
  • 财政年份:
    2019
  • 资助金额:
    $ 46.74万
  • 项目类别:
A complete map of the top 100 molecules from the gut microbiome
肠道微生物组前 100 个分子的完整图谱
  • 批准号:
    9162738
  • 财政年份:
    2016
  • 资助金额:
    $ 46.74万
  • 项目类别:
A complete map of the top 100 molecules from the gut microbiome
肠道微生物组前 100 个分子的完整图谱
  • 批准号:
    9540375
  • 财政年份:
    2016
  • 资助金额:
    $ 46.74万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 46.74万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了